Ophthalmic Business News

Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.

Harrow announced the relaunch of Triesence, a preservative-free synthetic corticosteroid, according to a press release.

Johnson & Johnson has expanded the roll-out of its presbyopia-correcting, full-visual range Tecnis Odyssey IOL, the company announced in a press release.

A common question we receive every 4 years is: How will the election impact my investments?

In this Healio Video Perspective from the Retina Society meeting, Pravin U. Dugel, MD, of Ocular Therapeutix shares positive updates on studies investigating Axpaxli, an axitinib implant for the treatment of retinal diseases.

The FDA granted fast track designation to brepocitinib for the treatment of nonanterior noninfectious uveitis, according to a press release from Priovant Therapeutics.

Roy Rubinfeld’s description of his experience as a clinician innovator is typical of those who attempt to bring a new drug, device or diagnostic from the bench to the bedside.

Time in the market is far more important than timing the market. Long-term investors will utilize both the strategies of dollar cost averaging and lump sum investing to reach their investment goals.

The Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its negative opinion on the marketing authorization application for intravitreal pegcetacoplan for geographic atrophy.

Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.